Analytical testing, QC

Charles River extends Huntington’s Disease collaboration, shutters site in San Diego

15-Apr-2019 By Melissa Fassbender

Charles River Laboratories has extended its ongoing collaboration with the CHDI Foundation by five-years – and is closing its San Diego, CA-based research model production facility.

Quantified ‘immune age’ could transform drug development, disease management: CytoReason

08-Apr-2019 By Melissa Fassbender

Researchers describe a technique to quantify a person’s “immune age,” information which could help design and analyze clinical trials – improving the drug development process, among other “impressive” possibilities, says industry expert.

Catalent expands HME capabilities at drug development center of excellence

08-Apr-2019 By Maggie Lynch

Catalent Pharma invests $5m in drug development center of excellence to expand its hot melt extrusion capabilities for formulation and drug delivery method optimization.

Constrained by outsourced testing? Study shows viability of in-house assessment

04-Apr-2019 By Melissa Fassbender

Clinical trials often rely on outsourced testing which poses potential logistical and cost challenges, though researchers recently demonstrated the viability of bringing these tests in-house to speed turnaround time – and more quickly match patients to...

People on the Move: Outsourcing-Pharma roundup March ‘19

29-Mar-2019 By Melissa Fassbender

The industry in March saw new c-suite appointments at CRF Bracket, PCI Pharma Services, George Clinical, and Paragon Bioservices – as well as moves to boost medical device and DMPK services at Premier Research and Sygnature Discovery, respectively.

On a Mission: LabCorp taps single cell-sequencing tech to accelerate drug development

28-Mar-2019 By Melissa Fassbender

LabCorp’s collaboration with Mission Bio will use single cell-sequencing technology to understand the genetics of rare cell populations, which could be key to making clinical trials successful, says CEO.

‘The UK may no longer be a country where bioanalytical innovation is feasible,’ says CRO on Brexit

28-Mar-2019 By Melissa Fassbender

Clinical trials in the UK are reportedly declining as the country grapples with Brexit – a change which could make access to preclinical and bioanalytical research materials, including NHPs, problematic, says QPS.

Trianni mouse model tapped for HIV vaccine research

25-Mar-2019 By Maggie Lynch

Trianni and San Diego Biomedical Research Institute enter license agreement for the use of the Trianni Mouse in HIV vaccine research.

‘Better decisions and shorter project timelines’: Optibrium taps InfoChem to up offering

19-Mar-2019 By Melissa Fassbender

Optibrium develops software for drug discovery and today announces a collaboration with InfoChem GmbH, a cheminformatics company, to provide users with a computer-aided synthesis design tool.

SenzaGen inks agreement with CRO to expand in vitro testing

18-Mar-2019 By Melissa Fassbender

In response to a growing interest in alternative testing methods, SenzaGen signs a license agreement with MB Research Labs to expand the use of its animal-free testing platform.

Charles River licenses rodent model for global diabetes reserach

14-Mar-2019 By Maggie Lynch

Charles River Labs enters a licensing agreement with Crown Bioscience to expand access to the latter’s diabetic rat model.

Drug development research agreement leverages simulation platform

12-Mar-2019 By Maggie Lynch

Drug development advisory firm Rosa & Co. enters research agreement with Chugai pharmaceutical to provide access to PhysioPD research services for translational biology.

People on the Move: Outsourcing-Pharma roundup February ‘19

01-Mar-2019 By Melissa Fassbender

Parexel boosts its oncology team, Premier Research has a new COO joining from PPD, and SGS names a new biologics manager, among other new hires in February.

Icon nabs molecular diagnostic lab to support precision medicine programs

26-Feb-2019 By Melissa Fassbender

Icon acquired the molecular diagnostic laboratory MolecularMD to further support precision medicine programs across all development phases.

Altasciences eyes early development space, CDMO addition

26-Feb-2019 By Melissa Fassbender

Consolidating its businesses under one brand, Altasciences is transitioning to an early drug development CRO – and looking to add a CDMO to manufacture drugs up to Phase II volumes.